The United States is allotting 3.2 billion dollars for the development of medicines against COVID-19 and other viruses. Health experts have been asking for a convenient medicine that people could take when symptoms first show. According to Dr. Anthony Fauci at a White House briefing last June 17, the said budget will focus on speeding up the research, trials, development, and formulation of the medicines. Early research suggests that Merck and Ridgeback Biotherapeutics’ antiviral medicine, molnupiravir, may decrease the risk of hospitalization if used right after infection by stopping the coronavirus from quickly spreading. However, it did not help patients who were already hospitalized with very serious condition. Medicines from other companies such as Pfizer, Roche, and AstraZeneca have been shown to help to avert hospitalization and shorten recovery time. Recently, the US has also allowed remdesivir, an antiviral medicine that has to be given only for COVID-19 patients at hospitals or medical clinics.